{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:45:42Z","timestamp":1790660742297,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Multidrug-resistant and extensively drug-resistant tuberculosis (MDR\/XDR-TB) is an emerging global health threat. Proper management of close contacts of infectious patients is increasingly important. However, no evidence-based recommendations for treating latent TB infection (LTBI) after MDR\/XDR-TB exposure (DR-LTBI) exist. An ultrashort regimen for LTBI caused by drug-susceptible strains (DS-LTBI) is also desirable. TMC207 has bactericidal and sterilizing activity in animal models of TB and improves the activity of current MDR-TB therapy in patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study was to determine whether TMC207 might enable short-course treatment of DR-LTBI and ultrashort treatment of DS-LTBI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using an established experimental model of LTBI chemotherapy in which mice are aerosol-immunized with a recombinant bacillus Calmette-Gu\u00e9rin vaccine before low-dose aerosol infection with Mycobacterium tuberculosis, the efficacy of TMC207 alone and in combination with rifapentine was compared with currently recommended control regimens as well as once-weekly rifapentine + isoniazid and daily rifapentine \u00b1 isoniazid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Outcomes included monthly lung colony-forming unit counts and relapse rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Results<\/jats:title>\n                    <jats:p>Lung colony-forming unit counts were stable at about 3.75 log10 for up to 7.5 months postinfection in untreated mice. Rifamycin-containing regimens were superior to isoniazid monotherapy. TMC207 exhibited sterilizing activity at least as strong as that of rifampin alone and similar to that of rifampin + isoniazid, but daily rifapentine +\/\u2212 isoniazid was superior to TMC207. Addition of TMC207 to rifapentine did not improve the sterilizing activity of rifapentine in this model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TMC207 has substantial sterilizing activity and may enable treatment of DR-LTBI in 3\u20134 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201103-0397oc","type":"journal-article","created":{"date-parts":[[2011,6,10]],"date-time":"2011-06-10T04:58:32Z","timestamp":1307681912000},"page":"732-737","source":"Crossref","is-referenced-by-count":61,"title":["Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection"],"prefix":"10.1093","volume":"184","author":[{"given":"Tianyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"State Key Laboratory of Respiratory Disease, Center for Infection and Immunity, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy N.","family":"Williams","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Andries","sequence":"additional","affiliation":[{"name":"Tibotec BVBA, Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,9,15]]},"reference":[{"key":"2026032101234010400_bib1","article-title":"Multidrug and extensively drug-resistant TB (M\/XDR-TB): 2010 global report on surveillance and response 2010","author":"World Health Organization","year":"2010"},{"key":"2026032101234010400_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(10)61972-1","article-title":"Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study","volume":"377","author":"Becerra","year":"2010","journal-title":"Lancet"},{"key":"2026032101234010400_bib3","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume-title":"MMWR Recomm Rep","author":"American Thoracic Society","year":"2000"},{"key":"2026032101234010400_bib4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199404283301718","article-title":"Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis","volume":"330","author":"Horn","year":"1994","journal-title":"N Engl J Med"},{"key":"2026032101234010400_bib5","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis","volume":"167","author":"Papastavros","year":"2002","journal-title":"CMAJ"},{"key":"2026032101234010400_bib6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/clinids\/24.6.1264","article-title":"Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin","volume":"24","author":"Ridzon","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2026032101234010400_bib7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1592\/phco.22.9.701.34065","article-title":"Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population","volume":"22","author":"Lou","year":"2002","journal-title":"Pharmacotherapy"},{"key":"2026032101234010400_bib8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.200905-0795OC","article-title":"Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection","volume":"180","author":"Zhang","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234010400_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"2026032101234010400_bib10","doi-asserted-by":"crossref","first-page":"25273","DOI":"10.1074\/jbc.M803899200","article-title":"Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis","volume":"283","author":"Koul","year":"2008","journal-title":"J Biol Chem"},{"key":"2026032101234010400_bib11","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1073\/pnas.0711697105","article-title":"The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis","volume":"105","author":"Rao","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032101234010400_bib12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jac\/dkq414","article-title":"Effects of low incubation temperatures on the bactericidal activity of anti-tuberculosis drugs","volume":"66","author":"Coleman","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026032101234010400_bib13","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1128\/AAC.00276-07","article-title":"Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910","volume":"51","author":"Lenaerts","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032101234010400_bib14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.00898-06","article-title":"Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis","volume":"51","author":"Ibrahim","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032101234010400_bib15","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.00766-06","article-title":"Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration","volume":"50","author":"Lounis","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032101234010400_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.200807-1152OC","article-title":"Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis","volume":"180","author":"Ibrahim","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234010400_bib17","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1128\/AAC.00934-10","article-title":"Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis","volume":"54","author":"Andries","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032101234010400_bib18","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"2026032101234010400_bib19","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/IAI.72.2.1065-1071.2004","article-title":"Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG","volume":"72","author":"Nuermberger","year":"2004","journal-title":"Infect Immun"},{"key":"2026032101234010400_bib20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1164\/rccm.200507-1047OC","article-title":"Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model","volume":"172","author":"Nuermberger","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234010400_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040344","article-title":"Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model","volume":"4","author":"Rosenthal","year":"2007","journal-title":"PLoS Med"},{"key":"2026032101234010400_bib22","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts","volume":"173","author":"Schechter","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234010400_bib23","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1164\/rccm.200507-1072OC","article-title":"Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis","volume":"172","author":"Rosenthal","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101234010400_bib24","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1128\/AAC.00830-09","article-title":"Paradoxical effect of isoniazid on the activity of rifampin\u2013pyrazinamide combination in a mouse model of tuberculosis","volume":"53","author":"Almeida","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032101234010400_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0962-8479(97)90016-2","article-title":"Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis","volume":"78","author":"Rhoades","year":"1997","journal-title":"Tuber Lung Dis"},{"key":"2026032101234010400_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tube.2006.11.003","article-title":"Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs","volume":"87","author":"Hunter","year":"2007","journal-title":"Tuberculosis (Edinb)"},{"key":"2026032101234010400_bib27","doi-asserted-by":"crossref","first-page":"e1000204","DOI":"10.1371\/journal.ppat.1000204","article-title":"Foamy macrophages from tuberculous patients\u2019 granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence","volume":"4","author":"Peyron","year":"2008","journal-title":"PLoS Pathog"},{"key":"2026032101234010400_bib28","article-title":"Tuberculosis Trials Consortium. The PREVENT TB Study (TB Trials Consortium Study 26) of 3 months of once-weekly rifapentine plus INH vs. 9 months of daily INH for treatment of latent TB infection: first report of results of a multi-center, randomized clinical trial","author":"Sterling","year":"2010"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/184\/6\/732\/67293614\/ajrccm_184_6_732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/184\/6\/732\/67293614\/ajrccm_184_6_732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:23:52Z","timestamp":1774070632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/184\/6\/732\/8508523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,9,15]]},"published-print":{"date-parts":[[2011,9,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201103-0397oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,9]]},"published":{"date-parts":[[2011,9]]}}}